Diabeloop announced today that it raised approximately $74.9 million (€70 million) in a Series C financing round. LBO France, a private equity player, led the financing round, while Terumo — with which Diabeloop has partnered since 2020 — also participated in the round. Innovacom joined LBO France and Terumo as new investors, according to a […]
Pain Management
Stevanato Group, Bexson expand partnership for wearable drug delivery device
Stevanato Group and Bexson Biomedical announced today that they agreed to expand their drug delivery collaboration. Under the agreement, Bexson has access to the use of a customized version of Stevanato’s SG EZ-be Pod wearable delivery system so it can develop new therapeutics for treating an array of mental health conditions, including treatment-resistant depression and […]
Virpax completes FDA-required preclinical studies for pain-treating topical spray
Virpax Pharmaceuticals (Nasdaq:VRPX) announced today that it completed all FDA-required preclinical studies for its Epoladerm product. Berwyn, Pennsylvania-based Virpax designed its Epoladerm investigational pre-filled topical spray analgesic product for the non-addictive management of chronic pain associated with osteoarthritis (OA) of the knee. Its completed investigational new drug application (IND)-enabling studies included dermal toxicity, sensitization, irritation, […]
Virpax touts study results for intranasal spray for treating acute, chronic pain
Virpax Pharmaceuticals (NSDQ:VRPX) today announced promising results from preclinical studies for its Envelta intranasal spray. Berwyn, Pennsylvania-based Virpax designed Envelta (NES100), an endogenous enkephalin intranasal spray, for treating acute and chronic pain, including pain associated with cancer. According to a news release, findings from preclinical dose range-finding studies for Envelta complement previous positive preclinical toxicology […]
Your favorite articles from Drug Delivery Business News in 2021
From continuous glucose monitors to insulin pens, plus needle-free injection devices and inhalers — here are the most popular articles on Drug Delivery Business News from 2021: Links to your favorite articles: Dexcom CEO Kevin Sayer says G7 will be ‘wonderful’ Eli Lilly partners with four companies on insulin pen tech Scancell picks PharmaJet’s needle-free […]
Avanos Medical to buy OrthogenRx for $160M
Avanos Medical today announced it entered into a definitive agreement to acquire OrthogenRx for $160 million. OrthogenRx makes viscosupplementation therapies to treat knee osteoarthritis pain, as well as commercial hyaluronic acid (HA) therapy products GenVisc 850 and TriVisc. Avanos will purchase the company for $130 million in cash at closing and an additional $30 million […]
Virpax reports positive non-human study results for topical spray film that treats chronic pain
Virpax Pharmaceuticals (NSDQ:VRPX) today reported positive results from a study of its Epoladerm treatment for chronic pain management. Berwyn, Pennsylvania-based Virpax designed Epoladerm, one of its lead investigational products, for managing pain associated with osteoarthritis of the knee. According to a news release, the company reported positive results following the completion of a toxicology and […]
FDA gives Bexson pre-IND guidance for ketamine formulation delivered by wearable pump
Bexson Biomedical announced today that it received pre-investigational new drug guidance from the FDA for its ketamine compound therapy. Santa Barbara, California-based Bexson develops the patented BB106 formulation, a ketamine therapy delivered through a wearable, subcutaneous patch pump in development with Stevanato Group. According to a news release, having reached the milestone of pre-IND guidance, […]
Drug delivery tech developer Virpax Pharmaceuticals prices $40M offering
Virpax Pharmaceuticals (NSDQ:VRPX) announced today that it priced an underwritten public offering worth approximately $40 million. Berwyn, Pennsylvania-based Virpax’s offering includes 6.67 million shares of common stock priced at $6 per share, totaling just over $40 million before deducting underwriting discounts and offering expenses. Additionally, the company granted underwriters a 45-day option to purchase up […]
FDA approves Nevro spinal cord stimulation to treat chronic pain with diabetic neuropathy
Nevro (NYSE:NVRO) announced today that it received FDA approval for its Senza system for treating chronic pain associated with PDN. Redwood City, Calif.-based Nevro’s Senza system’s approval is specific to Nevro’s 10 kHz stimulation, with the company touting that it now has the only spinal cord stimulation system approved by the FDA with a specific indication […]